Taysha Gene Therapies Files 8-K
Ticker: TSHA · Form: 8-K · Filed: Oct 2, 2025 · CIK: 1806310
Sentiment: neutral
Topics: sec-filing, 8-k, financials
TL;DR
Taysha Gene Therapies filed an 8-K on Oct 2, 2025, reporting events and financials.
AI Summary
Taysha Gene Therapies, Inc. filed an 8-K on October 2, 2025, reporting other events and financial statements. The company, incorporated in Delaware, is involved in biological products, specifically gene therapies, and is headquartered in Dallas, Texas.
Why It Matters
This filing indicates Taysha Gene Therapies is providing updates and financial information to the SEC, which is standard for publicly traded companies and can signal ongoing operational activities.
Risk Assessment
Risk Level: low — This is a routine SEC filing (8-K) reporting standard corporate events and financial information, not indicating any immediate material changes or risks.
Key Numbers
- 001-39536 — SEC File Number (Identifies the company's filing with the SEC.)
- 84-3199512 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- October 2, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 (address) — Principal Executive Offices
- (214) 612-0000 (phone_number) — Registrant's Telephone Number
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of October 2, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 2, 2025.
Where is Taysha Gene Therapies, Inc. headquartered?
Taysha Gene Therapies, Inc. is headquartered at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the SIC code for Taysha Gene Therapies, Inc.?
The Standard Industrial Classification (SIC) code for Taysha Gene Therapies, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2025-10-02 08:10:17
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value TSHA The Nasdaq Stock Mar
Filing Documents
- d61846d8k.htm (8-K) — 25KB
- d61846dex991.htm (EX-99.1) — 19KB
- 0001193125-25-227505.txt ( ) — 166KB
- tsha-20251002.xsd (EX-101.SCH) — 3KB
- tsha-20251002_lab.xml (EX-101.LAB) — 18KB
- tsha-20251002_pre.xml (EX-101.PRE) — 11KB
- d61846d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated October 2, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Taysha Gene Therapies, Inc. By: /s/ Kamran Alam Date: October 2, 2025 Kamran Alam Chief Financial Officer